Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1961 1
1962 5
1963 7
1964 7
1965 8
1966 5
1967 5
1968 9
1969 10
1970 7
1971 6
1972 4
1973 2
1974 2
1975 3
1976 1
1977 3
1978 3
1979 4
1980 3
1981 4
1982 8
1983 4
1984 7
1985 6
1986 6
1987 7
1988 13
1989 10
1990 9
1991 4
1992 2
1993 5
1994 4
1995 4
1996 7
1997 8
1998 4
1999 3
2000 1
2001 3
2002 4
2003 3
2004 5
2005 8
2006 6
2007 9
2008 12
2009 11
2010 11
2011 15
2012 16
2013 15
2014 9
2015 12
2016 15
2017 21
2018 21
2019 26
2020 32
2021 42
2022 34
2023 34
2024 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

537 results

Results by year

Filters applied: . Clear all
Page 1
JAK inhibitors ∼ overview∼.
Kameda H. Kameda H. Immunol Med. 2023 Sep;46(3):108-111. doi: 10.1080/25785826.2023.2183594. Epub 2023 Feb 27. Immunol Med. 2023. PMID: 36850046 Free article. Review.
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.
Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. Kondoh Y, et al. Among authors: kameda h. Respir Investig. 2021 Nov;59(6):709-740. doi: 10.1016/j.resinv.2021.04.011. Epub 2021 Oct 1. Respir Investig. 2021. PMID: 34602377 Review.
Reply.
Hirata A, Ogura T, Hayashi N, Takenaka S, Ito H, Mizushina K, Fujisawa Y, Yamashita N, Nakahashi S, Imamura M, Kujime R, Kameda H. Hirata A, et al. Among authors: kameda h. Arthritis Care Res (Hoboken). 2018 Jul;70(7):1119. doi: 10.1002/acr.23344. Epub 2018 Apr 26. Arthritis Care Res (Hoboken). 2018. PMID: 28834302 No abstract available.
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. van der Heijde D, et al. Among authors: kameda h. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788492 Free PMC article. Clinical Trial.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: kameda h. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
Non-radiographic axial spondyloarthritis.
Kameda H, Kobayashi S, Tamura N, Kadono Y, Tada K, Yamamura M, Tomita T. Kameda H, et al. Mod Rheumatol. 2021 Mar;31(2):277-282. doi: 10.1080/14397595.2020.1830512. Epub 2020 Oct 12. Mod Rheumatol. 2021. PMID: 32996809 Review.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: kameda h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Free article. Clinical Trial.
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G. Chandran V, et al. Among authors: kameda h. Rheumatology (Oxford). 2020 Oct 1;59(10):2774-2784. doi: 10.1093/rheumatology/kez684. Rheumatology (Oxford). 2020. PMID: 32031665 Free PMC article. Clinical Trial.
537 results